These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12824949)

  • 21. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.
    Vergne L; Stuyver L; Van Houtte M; Butel C; Delaporte E; Peeters M
    J Clin Virol; 2006 May; 36(1):43-9. PubMed ID: 16563858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
    Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
    Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
    Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
    Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali.
    Derache A; Traore O; Koita V; Sylla A; Tubiana R; Simon A; Canestri A; Carcelain G; Katlama C; Calvez V; Cisse M; Marcelin AG
    Antivir Ther; 2007; 12(1):123-9. PubMed ID: 17503757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
    Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
    J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
    Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P
    HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
    Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
    Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
    Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David DJ; Simon A; Lamotte C; Marcelin AG; Calvez V; Bricaire F; Costagliola D; Katlama C
    HIV Med; 2004 Sep; 5(5):352-9. PubMed ID: 15369510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
    Visco-Comandini U; Balotta C
    Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union.
    Vázquez de Parga E; Rakhmanova A; Pérez-Alvarez L; Vinogradova A; Delgado E; Thomson MM; Casado G; Sierra M; Muñoz M; Carmona R; Vega Y; Contreras G; Medrano L; Osmanov S; Nájera R
    J Med Virol; 2005 Nov; 77(3):337-44. PubMed ID: 16173024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].
    Sáez-Llorens X; Castrejón de Wong MC; Castaño E; de Suman O; Báez de Ulloa C; Redondo W; Espino M
    Rev Med Panama; 2001; 26():13-8. PubMed ID: 16161718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.